Print Page   |   Sign In   |   Register
Companies: AzuRx BioPharma (AZRX)

Company Profile

Trickle Research issues update of
AzurRx Biopharma, Inc.  5-2-18
12-24 Month Price Target $10.25

Click Here for Update Report

Trickle Research issues update of
AzurRx Biopharma, Inc.  4-16-18
12-24 Month Price Target $10.25

Click Here for Update Report

Trickle Research initiates coverage of
AzurRx Biopharma, Inc.  2-7-18
12-24 Month Price Target $10.25

Click Here for Research Report

Description

AzurRx BioPharma is a development stage biopharmaceutical company (NASDAQ: AZRX) focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome related conditions. Our therapeutic products will be administered to patients as oral non-systemic biologics. The company currently has two products in its pipeline: MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (for cystic fibrosis and chronic pancreatitis patients) and AZX1101, a recombinant enzyme for the prevention of hospital-acquired C.difficile infections. The company is headquartered in New York City, with scientific operations in Langlade, France.

 

Contact Information

760 Parkside Avenue
Downstate Biotechnology Incubator
Suite 304
Brooklyn, NY 11226 


 
Community Search
Sign In